If you have been reading about TB-500 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
== History == The first Outback Steakhouse location was opened on March 15, 1988, in Tampa, Florida. Canadian Outback Steakhouse restaurants began in 1996. In March 2009, Outback Steakhouse Canada abruptly closed all nine locations in the province of Ontario, citing poor economic conditions, but in June 2009, Outback Steakhouse opened a location in Niagara Falls, Ontario, with a second location later opening in the same city. As of 2024, these are the only Outback Steakhouse locations operating in Canada. Outback locations in Hawaii began to open in the mid 1990s, as part of a massive expansion across the country. On February 17, 2024, Outback’s parent company, Bloomin’ Brands, announced the permanent closure of all remaining Hawaii locations, as part of financial restructuring, citing a significant decrease in profits. This was part of a larger, mass closure of over 41 locations. All three locations in Hawaii were permanently closed by February 18, 2024. Outback Steakhouse opened in the UK with locations in Birmingham, Basildon, Enfield, Romford, Stevenage, Wandsworth in London and Staines. By September 2011, only its Basildon and Romford stores remained and they closed down on September 13, ending Outback's foray into the UK market. In 2006, a new Outback logo was introduced, dropping the old kangaroo logo for a more simplistic and modern Outback mountain range logo.
=== Alpha crystallins === The α-crystallins, which contributed to the discovery of crystallins as borrowed proteins, have continually supported the theory of gene sharing, and helped delineating the mechanisms used for gene sharing as well. There are two α-crystallin genes (αA and αB), which are about 55% identical in amino acid sequence. Expression studies in non-lens cells showed that the αB-crystallin, other than being a functional lens protein, is a functional small heat shock protein. αB-crystallin is induced by heat and other physiological stresses, and it can protect the cells from elevated temperatures and hypertonic stress. αB-crystallin is also overexpressed in many pathologies, including neurodegenerative diseases, fibroblasts of patients with Werner syndrome showing premature senescence, and growth abnormalities. In addition to being overexpressed under abnormal conditions, αB-crystallin is constitutively expressed in heart, skeletal muscle, kidney, lung and many other tissues. In contrast to αB-crystallin, except for low-level expression in the thymus, spleen and retina, αA-crystallin is highly specialized for expression in the lens and is not stress-inducible. However, like αB-crystallin, it can also function as molecular chaperone and protect against thermal stress.
Rush started to deviate from its 1980s style with the albums Presto (1989) and Roll the Bones (1991). Produced by record engineer and musician Rupert Hine, these two albums saw Rush shedding much of its keyboard-saturated sound. Beginning with Presto, the band opted for arrangements notably more guitar-centric than the previous two studio albums. Although synthesizers were still used, they were no longer featured as the centre-piece of Rush's compositions. Continuing this trend, Roll the Bones extended the use of the standard three-instrument approach with even less focus on synthesizers than its predecessor. While musically these albums do not deviate significantly from a general pop-rock sound, Rush incorporated other musical styles such as funk and hip-hop in "Roll the Bones" and jazz in the instrumental track "Where's My Thing?". "Show Don't Tell" from Presto was a No. 1 hit on the US Mainstream Rock Tracks Chart, and while the album reached the Top 10 in Canada, it was less successful in the US (No. 16) and the UK (No. 27). From Roll the Bones, "Dreamline" (No. 1) and "Ghost of a Chance" (No. 2) were successful on US Mainstream Rock Radio stations, marking a resurgence of Rush's album sales in the US (No. 3 and platinum), the UK (No. 10) and some other parts of northern Europe. The transition from synthesizers to more guitar-oriented and organic instrumentation continued with Counterparts (1993) and its follow-up, Test for Echo (1996), both produced in collaboration with Peter Collins.
Sources: en.wikipedia.org
== Software == Web-based Structural Analysis tool for any uploaded PDB file, producing Ramachandran plots, computing dihedral angles and extracting sequence from PDB Archived 2016-03-05 at the Wayback Machine Web-based tool showing Ramachandran plot of any PDB entry MolProbity web service that produces Ramachandran plots and other validation of any PDB-format file SAVES (Structure Analysis and Verification) — uses WHATCHECK, PROCHECK, and does its own internal Ramachandran Plot STING Pymol with the DynoPlot extension VMD, distributed with dynamic Ramachandran plot plugin WHAT CHECK, the stand-alone validation routines from the WHAT IF software UCSF Chimera, found under the Model Panel. Sirius Swiss PDB Viewer Archived 2019-01-18 at the Wayback Machine TALOS Zeus molecular viewer — found under "Tools" menu, high quality plots with regional contours Procheck Neighbor-Dependent and Neighbor-Independent Ramachandran Probability Distributions See also PDB for a list of similar software.
== Anatomy == Most starfish have five arms that radiate from a central disc, but the number varies with the group. Some species have six or seven arms and others have 10–15 arms. In Antarctic Labidiaster annulatus, the number of arms can exceed fifty. Evidence from gene expression finds that the starfish body corresponds to a head externally (with lips attached to the tube feet) and a torso internally. Starfish possess two vascular systems, one for transport of water to support locomotion and other functions, and another for circulation of blood.
== Dissolution and successor organisations == In December 1998, Democratic Left in England and Wales was formally dissolved and reconstituted as the New Times Network, which adopted a more inclusive membership policy that welcomed members of the Labour Party and other political organisations. The new body published a monthly magazine, New Times, and worked with the Fabian Society to organise the 'Getting Real' conference in June 1999. The New Times Network was subsequently renamed the New Politics Network in December 1999. In Scotland, the organisation evolved separately into Democratic Left Scotland, which was established in May 1998.
Sources: en.wikipedia.org
In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry). In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called "area under the curve" or AUC) gives insight into the extent of exposure to a drug and its clearance rate from the body.
237U is also produced via an (n,2n) reaction with 238U. This only happens with very energetic neutrons. 237Np is the product of alpha decay of 241Am, which is produced through neutron irradiation of uranium-238. Heavier isotopes of neptunium decay quickly, and lighter isotopes of neptunium cannot be produced by neutron capture, so chemical separation of neptunium from cooled spent nuclear fuel gives nearly pure 237Np. The short-lived heavier isotopes 238Np and 239Np, useful as radioactive tracers, are produced through neutron irradiation of 237Np and 238U respectively, while the longer-lived lighter isotopes 235Np and 236Np are produced through irradiation of 235U with protons and deuterons in a cyclotron. Artificial 237Np metal is usually isolated through a reaction of 237NpF3 with liquid barium or lithium at around 1200 °C and is most often extracted from spent nuclear fuel rods in kilogram amounts as a by-product in plutonium production.
=== Atmospheric sciences === In the atmospheric sciences, the vorticity equation can be stated in terms of the absolute vorticity of air with respect to an inertial frame, or of the vorticity with respect to the rotation of the Earth. The absolute version is
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.